Skip to main content

Table 2 Neurophysiological study in gastrocnemius and plantar muscles.

From: Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule

Group

(n)

Gastrocnemius muscle

Plantar muscle

  

Latency (ms)

CMAP (mV)

Latency (ms)

CMAP (mV)

3 months

     

WT

(6)

0.93 ± 0.04

51.9 ± 2.2

1.66 ± 0.08

6.49 ± 0.47

SOD control

(6)

1.11 ± 0.05

27.8 ± 2.9*

2.00 ± 0.10

2.55 ± 0.57*

SOD BDNF

(7)

1.12 ± 0.05

32.1 ± 5.0

1.89 ± 0.08

2.69 ± 0.44*

SOD TTC

(6)

1.04 ± 0.02

28.6 ± 3.5

1.95 ± 0.07

3.10 ± 0.52*

SOD BDNF-TTC

(8)

1.10 ± 0.05

32.1 ± 7.4

2.01 ± 0.11

2.64 ± 0.47*

4 months

     

WT

(6)

0.93 ± 0.05

53.6 ± 4.2

1.59 ± 0.03

6.89 ± 0.79

SOD control

(5)

1.09 ± 0.04

13.0 ± 2.6*

1.98 ± 0.03

0.89 ± 0.35*

SOD BDNF

(5)

1.10 ± 0.06

18.1 ± 3.1*

1.88 ± 0.04

1.52 ± 0.41*

SOD TTC

(5)

1.06 ± 0.03

18.7 ± 4.8*

2.03 ± 0.15*

1.91 ± 0.83*

SOD BDNF-TTC

(5)

1.11 ± 0.07

20.9 ± 9.3*

2.02 ± 0.16*

1.68 ± 0.71*

  1. Results of wild-type mice (WT), control SOD1G93A mice, and SOD1G93A mice treated with naked DNA encoding for BDNF, TTC, and BDNF-TTC are shown. Values are the mean ± SEM. CMAP, compound muscle action potential; n, number of mice.
  2. * P < 0.05 vs. WT group at the same age.